Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes

GAILLARD MARÍA EMILIA; BOTTERO DANIELA; ERREA AGUSTINA; ORMAZABAL MAXIMILIANO; ZURITA EUGENIA; MORENO GRISELDA; RUMBO MARTÍN; VAN DER LEY PETER; VAN DER ARK ARNO; HOZBOR DANIELA

Dublin

Simposio; 10th International Symposium on Bordetella; 2013

Trinity Biomedical Sciences Institute, Trinity College Dublin

To improve the pretussis disease control it seems to be necessary a new generation of vaccines capable of conferring both long-lasting immunity and protection against different Bordetella genotypes. Previously we have demostrated that the outer membrane vesicles (OMVs) obtained from B. pertussisare good vaccine candidates to protect against pertussis. Moreover, OMVs obtained from recombinant B. pertussis strain expressing PagL enzyme constitute a safer formulation (OMVsBpPagL), without altering protective immunity. In this work the OMVsBpPagL formulated with diphtheria and tetanus toxoids (TdapOMVsBpPagL) were used t evaluate its capacity to offer protection against the clinical isolate Bp106, selected as representative of Argentinean circulating bacteria, and to induce long-term immunity. To these aims, BALB/C mice qere immunized with TdapOMVsBpPagL and challenged with sublethal dose of B. pertussis. Significant differences between TdapOMVsBpPagL immunized animals and the negative control group were observed (p< 0.001). Comparisons with current comercial Tdap vaccines used at a dose in wich pertussis toxin level was equivalent to that of TdapOMVsBpPagL were performed.